On March 10, 2026, Aclaris Therapeutics, Inc. sold 5.7 million shares of common stock, raising $20.0 million through its sales agreement with Leerink Partners LLC and Cantor Fitzgerald & Co., with purchases made by Frazier Life Sciences, Kalehua Capital, and Adage Capital Partners LP.